On April 21, 2025 Jecho Biopharmaceuticals Co., Ltd. (hereinafter referred to as "Jechobio"), in collaboration with Wuhan Raydif Biotechnology Co., Ltd. (hereinafter referred to as "Raydif"), and Grand Pharmaceutical Group Limited (stock code: 00512.HK, hereinafter referred to as "Grand Pharma"), have jointly developed GPN02006, an innovative radionuclide-drug conjugate(RDC) targeting Glypican 3 (GPC3) (Press release, Jecho Laboratories, APR 21, 2025, View Source [SID1234653897]). The clinical results of GPN02006 were recently presented at the 2025 Future XDC New Drug Conference (list city location). Clinical strial data demonstrate that GPN02006 exhibits excellent safety and imaging efficacy, providing a novel solution for precision diagnosis of tumors with high GPC3 expression, such as liver cancer. No drug-related adverse reactions were reported in any of the subjects after administration, showcasing outstanding safety and tolerability; high-quality imaging can be achieved as early as 30 minutes post-dosing, fully meeting the rapid diagnostic needs for hepatocellular carcinoma.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
An Innovative Antibody Technology Platform as the Cornerstone of Precision Targeting
The remarkable clinical outcomes of GPN02006 represent a significant breakthrough in the field of radionuclide drugs and highlight the combined core R&D strengths of the three partners. Jechobio, leveraging its proprietary phage antibody library platform, VHH nanobody platform, and single B antibody discovery platform, has established a diverse antibody development system encompassing single-chain antibody fragments (scFv), nanobodies (VHH), Fab, IgG, and other formats. Through these platforms, Jechobio has successfully screened multiple innovative molecules that it is advancing to the clinic.
The GPC3 scFv targeting moiety of GPN02006 developed by Jechobio demonstrates three unique advantages: 1) High specificity and strong affinity -precise recognition of the GPC3 target ensures efficient tumor tissue targeting of the drug; 2) Excellent pharmacokinetic (PK) properties -perfect matching with the imaging agent lays the foundation for radionuclide drug development; 3) Outstanding safety -no adverse reactions were observed in preliminary human trials. These advantages demonstrate Jechobio’s innovative capabilities in the field of antibody drug research and development.
The Powerful Combination of Antibody + Radionuclide Drug"
The success of GPN02006 is a testament to the powerful combination of antibody technology + radionuclide drug development.
To date, this GPC3-targeting RDC clinical trial has enrolled over 80 patients and has demonstrated excellent performance in an investigator-initiated trial (IIT): 1) Exceptional safety: no drug-related adverse events were observed in any subjects; 2) Efficiency and convenience: effective imaging can be achieved 30 minutes post-injection; 3) Superior image quality: low background signal and strong tumor uptake provide a reliable basis for precise diagnosis of liver cancer.
With the rapid development of precision medicine, radionuclide-drug conjugates (RDCs) have emerged as a new frontier in tumor diagnosis and treatment.